References

MEK inhibitors in cancer treatment: structural insights, regulation, recent advances and future perspectives

10.1039/d3md00145h · 2023 · External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

Unresolved reference

External reference

FDA approves MEK inhibitor for rare neurofibromas

10.1038/d41573-025-00181-0 · 2025 · External reference

Mucocutaneous toxicities from MEK inhibitors: a scoping review of the literature

2024 · External reference

Unresolved reference

External reference

Adverse cutaneous reactions associated with MEK inhibitor therapy in a pediatric population

10.1016/j.jaad.2023.06.052 · 2023 · External reference

Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886)

10.1007/s10637-010-9567-3 · 2011 · External reference

Dermatologic effects of selumetinib in pediatric patients with neurofibromatosis type 1: clinical challenges and therapeutic management

10.3390/jcm13061792 · 2024 · External reference

Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: a multicenter study

10.1016/j.jaad.2020.07.044 · 2021 · External reference

Dermatological side effects of immunotherapy drugs and targeted cancer therapies: importance of dermatology and oncology collaboration

10.1177/1078155220970621 · 2021 · External reference

Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study

10.1093/annonc/mdx040 · 2017 · External reference

Development of cutaneous toxicities during selective anti-BRAF therapies: preventive role of combination with MEK inhibitors

10.2340/00015555-2488 · 2017 · External reference

Cutaneous reactions in pediatric patients treated with MEK inhibitors: a retrospective single-center study

10.1159/000539374 · 2024 · External reference

Adverse events associated with encorafenib plus binimetinib in the COLUMBUS study: incidence, course and management

10.1016/j.ejca.2019.07.016 · 2019 · External reference

The spectrum of cutaneous adverse events during encorafenib and binimetinib treatment in B-rapidly accelerated fibrosarcoma-mutated advanced melanoma

10.1111/jdv.15363 · 2019 · External reference

Inflammatory side effects of BRAF and MEK inhibitors

10.1097/cmr.0000000000000599 · 2019 · External reference

Cutaneous adverse reactions in B-RAF positive metastatic melanoma following sequential treatment with B-RAF/MEK inhibitors and immune checkpoint blockade or vice versa. A single-institutional case-series

10.1186/s40425-018-0475-y · 2019 · External reference

Cutaneous toxicities of MEK inhibitor use in children: a comparison of binimetinib and selumetinib

10.1111/pde.15792 · 2025 · External reference

Cutaneous adverse events to targeted therapies and immunotherapies in children: a retrospective study of 103 patients from two tertiary haemato-oncology referral centres

10.2340/00015555-3867 · 2021 · External reference

Cutaneous toxicities of mitogen-activated protein kinase inhibitors in children and young adults with neurofibromatosis-1

10.1007/s11060-024-04617-2 · 2024 · External reference

Cutaneous reactions to targeted therapies in children with CNS tumors: a cross-sectional study

10.1002/pbc.27682 · 2019 · External reference

Cutaneous adverse events in patients receiving anticancer therapy in a tertiary hospital setting: the old and the new

10.1111/ijd.15081 · 2021 · External reference

Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines

10.1016/j.annonc.2020.11.005 · 2021 · External reference

MEK inhibitor-induced dusky erythema: characteristic drug hypersensitivity manifestation in 3 patients

10.1001/jamadermatol.2014.3207 · 2015 · External reference

The use of MEK inhibitors in neurofibromatosis type 1-associated tumors and management of toxicities

10.1634/theoncologist.2020-0069 · 2020 · External reference

BRAF and MEK inhibitors in pediatric glioma: new therapeutic strategies, new toxicities

10.1080/17425255.2016.1214710 · 2016 · External reference

Management of BRAF and MEK inhibitor toxicities in patients with metastatic melanoma

10.1177/1758834014566428 · 2015 · External reference

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

10.1016/s1470-2045(19)30277-3 · 2019 · External reference

Unresolved reference

External reference

INDIVIDUAL ARTICLE: NECOM 5: algorithm for the treatment and supportive management of targeted therapy-related cutaneous adverse events

2025 · External reference

Consensus recommendations on management of selumetinib-associated adverse events in pediatric patients with neurofibromatosis type 1 and plexiform neurofibromas

2024 · External reference

INDIVIDUAL ARTICLE: USCOM IV algorithm for the prevention and management of targeted therapy-related cutaneous adverse events

10.36849/jdd.43661 · 2024 · External reference

Successful treatment of a child with MEK inhibitor-induced acneiform eruption with low-dose isotretinoin

10.1111/pde.14959 · 2022 · External reference

Chemotherapy-associated paronychia treated with 2% povidone–iodine: a series of cases

10.2147/cmar.s139301 · 2017 · External reference

MEK inhibitor-induced paronychia in a paediatric population: a tertiary centre experience

10.1111/ajd.14079 · 2023 · External reference

Drug-induced photosensitivity associated with anticancer therapies

2024 · External reference

Anticancer treatments and photosensitivity

10.1111/jdv.18200 · 2022 · External reference

Prophylaxis and management of skin toxicities

10.1159/000497232 · 2019 · External reference

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management

10.2147/ccid.s140796 · 2017 · External reference

Adverse cutaneous effects of mitogen-activated protein kinase inhibitors in children

10.1111/pde.14354 · 2021 · External reference

Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome

10.1016/j.clindermatol.2020.06.008 · 2020 · External reference

Drug rash with eosinophilia and systemic symptoms (DRESS) syndrome in childhood: a narrative review

2023 · External reference

Cutaneous side effects of modern targeted therapy and immunotherapy in patients with dermatological malignancies

10.3390/cancers15123126 · 2023 · External reference

Risk of selected dermatological toxicities in cancer patients treated with MEK inhibitors: a comparative systematic review and meta-analysis

2015 · External reference

Diagnosis and management of dermatologic adverse events from systemic melanoma therapies

10.1007/s40257-023-00790-8 · 2023 · External reference

Successful treatment of MEK inhibitor-induced paronychia in neurofibromatosis with photodynamic therapy: a case report and review of the therapeutic options

10.3390/jcm14041104 · 2025 · External reference

Reacciones capilares de las nuevas terapias diana dirigidas contra el cáncer

10.1016/j.ad.2018.10.019 · 2019 · External reference

Selumetinib side effects in children treated for plexiform neurofibromas: first case reports of peripheral edema and hair color change

10.1186/s12887-021-02530-5 · 2021 · External reference